Overview

A Study to Evaluate the Efficacy and Safety of KW-0761 in Chinese Subjects With Mycosis Fungoides or Sézary Syndrome Previously Treated With Systemic Therapy

Status:
ACTIVE_NOT_RECRUITING

Trial end date:
2025-11-13

Target enrollment:

Participant gender:

Summary

The purpose of the study is to evaluate the efficacy and safety of mogamulizumab (KW-0761) in chinese subjects with mycosis fungoides or sézary syndrome previously treated with systemic therapy

Phase:

PHASE4

Details

Lead Sponsor:

Kyowa Kirin China Pharmaceutical Co., Ltd.

Treatments:

mogamulizumab